EP2729151B1 - Pharmaceutical composition, methods for treating and uses thereof - Google Patents
Pharmaceutical composition, methods for treating and uses thereof Download PDFInfo
- Publication number
- EP2729151B1 EP2729151B1 EP12730993.8A EP12730993A EP2729151B1 EP 2729151 B1 EP2729151 B1 EP 2729151B1 EP 12730993 A EP12730993 A EP 12730993A EP 2729151 B1 EP2729151 B1 EP 2729151B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- glucose
- obesity
- patient
- equal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor for use in a method for preventing, slowing the progression of, delaying or treating renal hyperfiltrative injury in a patient diagnosed with type 1 diabetes mellitus. Furthermore the invention relates to a pharmaceutical composition comprising the SGLT2 inhibitor 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-[4-( (S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene for use in a method for preventing, slowing the progression of, delaying or treating renal hyperfiltration in a patient diagnosed with type 1 diabetes mellitus.
- Kidneys are bean-shaped organs, located near the middle of the back. Inside each kidney about a million tiny structures called nephrons filter blood. They remove waste products and extra water, which become urine. Damage to the nephrons represents one form of kidney disease. This damage may leave kidneys unable to remove wastes. Some damage, e.g. damage related to hyperfiltration can occur slowly over years, initially often without obvious symptoms.
- the 'hyperfiltrative hypothesis' implies that the excess demand on a limited renal reserve produces adaptive and ultimately pathologic changes in the kidney which finally lead to 'nephron exhaustion'.
- hyperfiltration is hypothesized to be an early link in the chain of events that lead from intraglomerular hypertension to albuminuria and, subsequently, to reduced Glomerular Filtration Rate (GFR). Based on this hypothesis such a finding therefore represents a risk for subsequent renal injury and could be classified as an early manifestation of renal damage often referred to as the hyperfiltrative stage.
- Such renal hyperfiltration can lead to early glomerular lesions and to microalbuminuria, which itself can lead to macroalbuminuria and to end-stage renal disease.
- WO 2008/055940 A2 relates to pharmaceutical compositions comprising a SGLT2 inhibitor and an antidiabetic agent selected from a group as specified.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the SGLT2 inhibitor 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-[4-( (S)- tetrahydrofuran-3-yloxy)-benzyl]-benzene for use in a method for preventing, slowing the progression of, delaying or treating renal hyperfiltrative injury in a patient diagnosed with type 1 diabetes mellitus in need thereof.
- the patient is an individual diagnosed or showing one or more of the following conditions:
- the patient has an GFR equal to or greater than 125 mL/min/1.73 m 2 . In a further aspect, the patient has an GFR equal to or greater than 140 mL/min/1.73 m 2 .
- the patient :
- the pharmaceutical composition additionally comprises one or more pharmaceutically acceptable carriers.
- the pharmaceutical composition comprises the SGLT-2 inhibitor in a range from about 10 mg to 25 mg. In one aspect, the pharmaceutical composition comprises 10 mg or 25 mg of the SGLT-2 inhibitor.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the SGLT2 inhibitor 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-[4-( (S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene for use in a method for preventing, slowing the progression of, delaying or treating renal hyperfiltration in a patient diagnosed with type 1 diabetes mellitus.
- the patient is an individual diagnosed or showing one or more of the following conditions:
- the patient has an GFR equal to or greater than 125 mL/min/1.73 m 2 . In a further aspect, the patient has an GFR equal to or greater than 140 mL/min/1.73 m 2 .
- the patient :
- the pharmaceutical composition additionally comprises one or more pharmaceutically acceptable carriers.
- the pharmaceutical composition comprises the SGLT-2 inhibitor in a range from about 10 mg to 25 mg. In one aspect, the pharmaceutical composition comprises 10 mg or 25 mg of the SGLT-2 inhibitor.
- active ingredient of a pharmaceutical composition according to the present invention means the SGLT2 inhibitor according to the present invention.
- An “active ingredient is also sometimes referred to herein as an "active substance”.
- hyperfiltration is defined as an elevation in the filtration rate of the renal glomeruli.
- hyperfiltration is defined as a whole kidney filtration rate equal to or greater than 125 mL/min/1.73 m 2 , especially equal to or greater than 140 mL/min/1.73 m 2 , as measured using a method described hereinbelow.
- Hyperfiltration may also be defined as related to an absolute GFR greater to the 90 th , or the 95 th , percentile in the studied population after adjusting for sex, age, weight, height, and the use of ACE inhibitors or ARB (see Melsom et al. Diabetes Care 2011; DOI: 10.2337/dc11-0235 ).
- GFR glomerular filtration rate
- the glomerular filtration rate (GFR) is defined as the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. It is indicative of overall kidney function.
- the glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.
- the GFR is typically recorded in units of volume per time, e.g., milliliters per minute and the formula below can be used:
- GFR Urine Concentration ⁇ Urine Volume / Plasma Conentration
- the "estimated glomerular filtration rate (eGFR)" is defined as derived at screening from serum creatinine values based on e.g., the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the Cockcroft-Gault formula or the Modification of Diet in Renal Disease (MDRD) formula, which are all known in the art.
- Subjects with normal renal function are defined as eGFR ⁇ 90 ml/min.
- Subjects with mild impairment of renal function as defined eGFR ⁇ 60 and ⁇ 90 ml/min).
- renal hyperfiltrative injury is defined as a manifestation of renal damage caused predominantly by renal hyperfiltration, which often is an early link in the chain of events to further renal injury, acknowledging that hyperfiltration often works in concert with other chronic kidney disease risk factors in the pathogenesis of renal injury.
- body mass index or "BMI” of a human patient is defined as the weight in kilograms divided by the square of the height in meters, such that BMI has units of kg/m 2 .
- overweight is defined as the condition wherein the adult individual of Europide origin has a BMI greater than or 25 kg/m 2 and less than 30 kg/m 2 .
- overweight is defined as the condition wherein the adult individual has a BMI greater than or 23 kg/m 2 and less than 25 kg/m 2 .
- overweight and pre-obese are used interchangeably.
- the term "obesity” is defined as the condition wherein the adult individual of Europid origin has a BMI equal to or greater than 30 kg/m 2 .
- the term obesity may be categorized as follows: the term “class I obesity” is the condition wherein the BMI is equal to or greater than 30 kg/m 2 but lower than 35 kg/m 2 ; the term “class II obesity” is the condition wherein the BMI is equal to or greater than 35 kg/m 2 but lower than 40 kg/m 2 ; the term “class III obesity” is the condition wherein the BMI is equal to or greater than 40 kg/m 2 .
- the term "obesity” is defined as the condition wherein the adult individual has a BMI equal or greater than 25 kg/m 2 .
- Obesity in Asians may be categorized further as follows: the term “class I obesity” is the condition wherein the BMI is equal to or greater than 25 kg/m 2 but lower than 30 kg/m 2 ; the term “class II obesity” is the condition wherein the BMI is equal to or greater than 30 kg/m 2 .
- visceral obesity is defined as the condition wherein a waist-to-hip ratio of greater than or equal to 1.0 in men and 0.8 in women is measured. It defines the risk for insulin resistance and the development of pre-diabetes.
- abdominal obesity is usually defined as the condition wherein the waist circumference is > 40 inches or 102 cm in men, and is > 35 inches or 94 cm in women (for normal ranges of popupations, see for example " Joint scientific statement (IDF, NHLBI, AHA, WHO, IAS, IASO). Circulation 2009; 120:1640-1645 ").
- abdominal obesity may be defined as waist circumference ⁇ 85 cm in men and ⁇ 90 cm in women (see e.g. investigating committee for the diagnosis of metabolic syndrome in Japan).
- the term "morbid obesity” is defined herein as a condition in which the individual of Europid origin has a BMI > 40 or has a BMI > 35 and a comorbidity such as diabetes melitus or hypertension (see World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report on a WHO Consultation. World Health Organ Tech Rep Ser. 2000; 894: i-xii, 1-253 ).
- euglycemia is defined as the condition in which a subject has a fasting blood glucose concentration within the normal range, greater than 70 mg/dL (3.89 mmol/L) and less than 100 mg/dL (5.6 mmol/L), and a 2h postprandial glucose concentration less than 140 mg/dl.
- fasting has the usual meaning as a medical term.
- hypoglycemia is defined as the condition in which a subject has a fasting blood glucose concentration above the normal range, greater than 100 mg/dL (5.6 mmol/L).
- fasting has the usual meaning as a medical term.
- hypoglycemia is defined as the condition in which a subject has a blood glucose concentration below the normal range, in particular below 70 mg/dL (3.89 mmol/L).
- postprandial hyperglycemia is defined as the condition in which a subject has a 2 hour postprandial blood glucose or serum glucose concentration greater than 200 mg/dL (11.11 mmol/L).
- IGF paired fasting blood glucose
- a subject with "normal fasting glucose” has a fasting glucose concentration smaller than 100 mg/dl, i.e. smaller than 5.6 mmol/l.
- ITT paired glucose tolerance
- the abnormal glucose tolerance i.e. the 2 hour postprandial blood glucose or serum glucose concentration can be measured as the blood sugar level in mg of glucose per dL of plasma 2 hours after taking 75 g of glucose after a fast.
- a subject with "normal glucose tolerance” has a 2 hour postprandial blood glucose or serum glucose concentration smaller than 140 mg/dl (7.78 mmol/L).
- hyperinsulinemia is defined as the condition in which a subject with insulin resistance, with or without euglycemia, has fasting or postprandial serum or plasma insulin concentration elevated above that of normal, lean individuals without insulin resistance, having a waist-to-hip ratio ⁇ 1.0 (for men) or ⁇ 0.8 (for women).
- Insulin-sensitizing As insulin-sensitizing, “insulin resistance-improving” or “insulin resistance-lowering” are synonymous and used interchangeably.
- insulin resistance is defined as a state in which circulating insulin levels in excess of the normal response to a glucose load are required to maintain the euglycemic state ( Ford ES, et al. JAMA. (2002) 287:356-9 ).
- a method of determining insulin resistance is the euglycaemic-hyperinsulinaemic clamp test. The ratio of insulin to glucose is determined within the scope of a combined insulin-glucose infusion technique. There is found to be insulin resistance if the glucose absorption is below the 25th percentile of the background population investigated (WHO definition).
- insulin resistance the response of a patient with insulin resistance to therapy, insulin sensitivity and hyperinsulinemia may be quantified by assessing the "homeostasis model assessment to insulin resistance (HOMA-IR)" score, a reliable indicator of insulin resistance ( Katsuki A, et al. Diabetes Care 2001; 24: 362-5 ). Further reference is made to methods for the determination of the HOMA-index for insulin sensitivity ( Matthews et al., Diabetologia 1985, 28: 412-19 ) , of the ratio of intact proinsulin to insulin ( Forst et al., Diabetes 2003, 52(Suppl.1): A459 ) and to an euglycemic clamp study.
- HOMA-IR homeostasis model assessment to insulin resistance
- HOMA-IR homeostasis assessment model
- the patient's triglyceride concentration is used, for example, as increased triglyceride levels correlate significantly with the presence of insulin resistance.
- Patients with a predisposition for the development of IGT or IFG or type 2 diabetes are those having euglycemia with hyperinsulinemia and are by definition, insulin resistant.
- a typical patient with insulin resistance is usually overweight or obese. If insulin resistance can be detected, this is a particularly strong indication of the presence of pre-diabetes. Thus, it may be that in order to maintain glucose homoeostasis a person needs 2-3 times as much insulin as a healthy person, without this resulting in any clinical symptoms.
- beta-cell function can be measured for example by determining a HOMA-index for beta-cell function ( Matthews et al., Diabetologia 1985, 28: 412-19 ) , the ratio of intact proinsulin to insulin ( Forst et al., Diabetes 2003, 52(Suppl.1): A459 ) , the insulin/C-peptide secretion after an oral glucose tolerance test or a meal tolerance test, or by employing a hyperglycemic clamp study and/or minimal modeling after a frequently sampled intravenous glucose tolerance test ( Stumvoll et al., Eur J Clin Invest 2001, 31: 380-81 ).
- pre-diabetes is the condition wherein an individual is pre-disposed to the development of type 2 diabetes.
- Pre-diabetes extends the definition of impaired glucose tolerance to include individuals with a fasting blood glucose within the high normal range ⁇ 100 mg/dL ( J. B. Meigs, et al. Diabetes 2003; 52:1475-1484 ) and fasting hyperinsulinemia (elevated plasma insulin concentration).
- the scientific and medical basis for identifying pre-diabetes as a serious health threat is laid out in a Position Statement entitled " The Prevention or Delay of Type 2 Diabetes” issued jointly by the American Diabetes Association and the National Institute of Diabetes and Digestive and Kidney Diseases (Diabetes Care 2002; 25:742-749 ).
- insulin resistance is defined as the clinical condition in which an individual has a HOMA-IR score > 4.0 or a HOMA-IR score above the upper limit of normal as defined for the laboratory performing the glucose and insulin assays, or values above the 75 th percentile of the reference population.
- type 2 diabetes is defined as the condition in which a subject has a fasting (i.e., no caloric intake for 8 hours) blood glucose or serum glucose concentration greater than 125 mg/dL (6.94 mmol/L), when measured at minimum two independent occasions.
- a fasting i.e., no caloric intake for 8 hours
- serum glucose concentration greater than 125 mg/dL (6.94 mmol/L)
- the measurement of blood glucose values is a standard procedure in routine medical analysis.
- Type 2 diabetes is also defined as the condition in which a subject has HbA1c equal to, or greater than 6.5%, a two hour plasma glucose equal to, or greater than 200 g/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT) or a random glucose concentration equal to, or greater than 200 mg/dL (11.1 mmol/L) in conjunction with classic symptoms of hyperglycaemia or hyperglycaemic crisis.
- OGTT oral glucose tolerance test
- a test result diagnostic of diabetes should be repeated to rule out laboratory error.
- HbA1c should be performed using a method certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay. If a OGTT is carried out, the blood sugar level of a diabetic will be in excess of 200 mg of glucose per dL (11.1 mmol/l) of plasma 2 hours after 75 g of glucose have been taken on an empty stomach. In a glucose tolerance test 75 g of glucose are administered orally to the patient being tested after aminimun of 8 hours, typicaly after 10-12 hours, of fasting and the blood sugar level is recorded immediately before taking the glucose and 1 and 2 hours after taking it.
- NGSP National Glycohemoglobin Standardization Program
- DCCT Diabetes Control and Complications Trial
- the blood sugar level before taking the glucose will be between 60 and 110 mg per dL of plasma, less than 200 mg per dL 1 hour after taking the glucose and less than 140 mg per dL after 2 hours. If after 2 hours the value is between 140 and 200 mg, this is regarded as abnormal glucose tolerance.
- early stage type 2 diabetes mellitus includes patients with a long-standing duration of diabetes, secondary drug failure, indication for insulin therapy and potentially progression to micro- and macrovascular complications e.g. diabetic nephropathy, or coronary heart disease (CHD).
- diabetes includes patients with a long-standing duration of diabetes, secondary drug failure, indication for insulin therapy and potentially progression to micro- and macrovascular complications e.g. diabetic nephropathy, or coronary heart disease (CHD).
- CHD coronary heart disease
- type 1 diabetes is defined as the condition in which a subject has, in the presence of autoimmunity towards the pancreatic beta-cell (i.e. detection of circulating islet cell autoantibodies ["type 1A diabetes mellitus”], i.e., at least one of: GAD65 [glutamic acid decarboxylase-65], ICA [islet-cell cytoplasm], IA-2 [intracytoplasmatic domain of the tyrosine phosphatase-like protein IA-2], ZnT8 [zinc-transporter-8] or anti-insulin; or other signs of automimmunity without the presence of typical circulating autoantibodies [type 1B diabetes], i.e.
- Type 1 diabetes is also defined as the condition in which a subject has, in the presence of autoimmunity towards the pancreatic beta-cell, HbA1c equal to, or greater than 6.5%, a two hour plasma glucose equal to, or greater than 200 g/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT) or a random glucose equal to, or greater than 200 mg/dL (11.1 mmol/L) in conjunction with classic symptoms of hyperglycaemia or hyperglycaemic crisis.
- HbA1c i.e., no caloric intake for 8 hours
- a fasting i.e., no caloric intake for 8 hours
- blood glucose or serum glucose concentration greater than 125 mg/dL (6.94 mmol/L.
- Type 1 diabetes is also defined as the condition in which a subject has, in the presence of autoimmunity towards the pancreatic beta-cell, HbA1c equal to, or greater than 6.5%, a two hour plasma glucose equal to, or
- a test result diagnostic of diabetes should be repeated to rule out laboratory error.
- the measurement of blood glucose values is a standard procedure in routine medical analysis.
- the assessment of HbA1c should be performed using a method certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay. If a OGTT is carried out, the blood sugar level of a diabetic will be in excess of 200 mg of glucose per dL (11.1 mmol/l) of plasma 2 hours after 75 g of glucose have been taken on an empty stomach, in the presence of autoimmunity towards the pancreatic beta cell.
- NGSP National Glycohemoglobin Standardization Program
- DCCT Diabetes Control and Complications Trial
- a glucose tolerance test 75 g of glucose are administered orally to the patient being tested after a minimum of 8 hours, typically, 10-12 hours, of fasting and the blood sugar level is recorded immediately before taking the glucose and 1 and 2 hours after taking it.
- a genetic predisposition is present (e.g. HLA, INS VNTR and PTPN22), but this is not always the case.
- MODY monosomal growth factor
- MODY 1,2.3.4 a monogenic form for diabetes that, according to gene affects, is split into MODY variants, e.g., MODY 1,2.3.4 etc.
- LADA latent autoimmune diabetes of adults
- patients that has a clinical diagnosis of type 2 diabetes, but who is being detected to have autoimmunity towards the pancreatic beta cell refers to patients that has a clinical diagnosis of type 2 diabetes, but who is being detected to have autoimmunity towards the pancreatic beta cell.
- HbA1c refers to the product of a non-enzymatic glycation of the haemoglobin B chain. Its determination is well known to one skilled in the art. In monitoring the treatment of diabetes mellitus the HbA1c value is of exceptional importance. As its production depends essentially on the blood sugar level and the life of the erythrocytes, the HbA1c in the sense of a "blood sugar memory” reflects the average blood sugar levels of the preceding 4-6 weeks. Diabetic patients whose HbA1c value is consistently well adjusted by intensive diabetes treatment (i.e. ⁇ 6.5 % of the total haemoglobin in the sample), are significantly better protected against diabetic microangiopathy.
- metformin on its own achieves an average improvement in the HbA1c value in the diabetic of the order of 1.0 - 1.5 %.
- This reduction of the HbA1C value is not sufficient in all diabetics to achieve the desired target range of ⁇ 6.5 % and preferably ⁇ 6 % HbA1c.
- insufficient glycemic control or "inadequate glycemic control” in the scope of the present invention means a condition wherein patients show HbA1c values above 6.5 %, in particular above 7.0 %, even more preferably above 7.5 %, especially above 8 %.
- the "metabolic syndrome”, also called “syndrome X” (when used in the context of a metabolic disorder), also called the “dysmetabolic syndrome” is a syndrome complex with the cardinal feature being insulin resistance ( Laaksonen DE, et al. Am J Epidemiol 2002;156:1070-7 ).
- ATP III/NCEP guidelines Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA: Journal of the American Medical Association (2001) 285:2486-2497 )
- diagnosis of the metabolic syndrome is made when three or more of the following risk factors are present:
- Triglycerides and HDL cholesterol in the blood can also be determined by standard methods in medical analysis and are described for example in Thomas L (Editor): "Labor und Diagnose", TH-Books Verlagsgesellschaft mbH, Frankfurt/Main, 2000 .
- hypertension is diagnosed if the systolic blood pressure (SBP) exceeds a value of 140 mm Hg and diastolic blood pressure (DBP) exceeds a value of 90 mm Hg. If a patient is suffering from manifest diabetes it is currently recommended that the systolic blood pressure be reduced to a level below 130 mm Hg and the diastolic blood pressure be lowered to below 80 mm Hg.
- SBP systolic blood pressure
- DBP diastolic blood pressure
- NODAT new onset diabetes after transplantation
- PTMS post-transplant metabolic syndrome
- IDF International Diabetes Federation
- PTMS post-transplant metabolic syndrome
- NODAT and/or PTMS are associated with an increased risk of micro- and macrovascular disease and events, graft rejection, infection, and death.
- a number of predictors have been identified as potential risk factors related to NODAT and/or PTMS including a higher age at transplant, male gender, the pre-transplant body mass index, pre-transplant diabetes, and immunosuppression.
- gestational diabetes denotes a form of the diabetes which develops during pregnancy and usually ceases again immediately after the birth.
- Gestational diabetes is diagnosed by a screening test which often is carried out between the 24th and 28th weeks of pregnancy, but could be conducted at any time during pregnancy, in particular if previous gestational diabetes has been diagnosed. It is usually a simple test in which the blood sugar level is measured e.g., one hour after the administration of 50 g of glucose solution. If this 1 h level is above 140 mg/dl, gestational diabetes is suspected.
- Final confirmation may be obtained by a standard glucose tolerance test, for example with 75 g of glucose; which also serve as a diagnostic test in the absence of the 50 g challenge.
- hyperuricemia denotes a condition of high serum total urate levels.
- uric acid concentrations between 3.6 mg/dL (ca. 214 ⁇ mol/L) and 8.3 mg/dL (ca. 494 ⁇ mol/L) are considered normal by the American Medical Association.
- High serum total urate levels, or hyperuricemia are often associated with several maladies. For example, high serum total urate levels can lead to a type of arthritis in the joints kown as gout. Gout is a condition created by a build up of monosodium urate or uric acid crystals on the articular cartilage of joints, tendons and surrounding tissues due to elevated concentrations of total urate levels in the blood stream.
- uric acid The build up of urate or uric acid on these tissues provokes an inflammatory reaction of these tissues. Saturation levels of uric acid in urine may result in kidney stone formation when the uric acid or urate crystallizes in the kidney. Additionally, high serum total urate levels are often associated with the so-called metabolic syndrome, including cardiovascular disease and hypertension.
- SGLT2 inhibitor in the scope of the present invention relates to compounds, in particular to glucopyranosyl-derivatives, i.e. compounds having a glucopyranosyl-moiety, which show an inhibitory effect on the sodium-glucose transporter 2 (SGLT2), in particular the human SGLT2 (hSGLT2).
- the inhibitory effect on hSGLT2 measured as IC50 is preferably below 1000 nM, even more preferably below 100 nM, most preferably below 50 nM.
- the inhibitory effect on hSGLT2 can be determined by methods known in the literature, in particular as described in the application WO 2005/092877 or WO 2007/093610 (pages 23/24).
- the term "SGLT2 inhibitor” also comprises any pharmaceutically acceptable salts thereof, hydrates and solvates thereof, including the respective crystalline forms.
- treatment and “treating” comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form.
- Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease.
- compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy.
- prophylactically treating means a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.
- tablette comprises tablets without a coating and tablets with one or more coatings. Furthermore the “term” tablet comprises tablets having one, two, three or even more layers and press-coated tablets, wherein each of the beforementioned types of tablets may be without or with one or more coatings.
- tablette also comprises mini, melt, chewable, effervescent and orally disintegrating tablets.
- pharmacopoe and “pharmacopoeias” refer to standard pharmacopoeias such as the "USP 31-NF 26 through Second Supplement” (United States Pharmacopeial Convention) or the "European Pharmacopoeia 6.3" ( European Directorate for the Quality of Medicines and Health Care, 2000-2009 ).
- Figure 1 shows an X-ray powder diffractogram of the crystalline form (I.9X) of the compound (1.9).
- Figure 2 shows the thermoanalysis and determination of the melting point via DSC of the crystalline form (I9.X) of the compound (1.9).
- the present invention provides a pharmaceutical composition for use in a method for preventing, slowing the progression of, delaying or treating renal hyperfiltrative injury in a patient with type 1 diabetes mellitus.
- the present invention further provides a pharmaceutical composition for use in a method for preventing, slowing the progression of, delaying or treating renal hyperfiltration in a patient diagnosed with type 1 diabetes mellitus.
- the pharmaceutical compositions of the present invention comprise the SGLT-2 inhibitor 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-[4-( (S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene.
- SGLT2 inhibitors represent a novel class of agents that are being developed for the treatment or improvement in glycemic control in patients with type 2 diabetes.
- Glucopyranosyl-substituted benzene derivatives are described in the prior art as SGLT2 inhibitors, for example in WO 01/27128 , WO 03/099836 , WO 2005/092877 , WO 2006/034489 , WO 2006/064033 , WO 2006/117359 , WO 2006/117360 , WO 2007/025943 , WO 2007/028814 , WO 2007/031548 , WO 2007/093610 , WO 2007/128749 , WO 2008/049923 , WO 2008/055870 , WO 2008/055940 .
- the glucopyranosyl-substituted benzene derivatives are proposed as inducers of urinary sugar excretion and as medicaments in the treatment of diabetes.
- Renal filtration and reuptake of glucose contributes, among other mechanisms, to the steady state plasma glucose concentration and can therefore serve as an antidiabetic target.
- Reuptake of filtered glucose across epithelial cells of the kidney proceeds via sodium-dependent glucose cotransporters (SGLTs) located in the brush-border membranes in the tubuli along the sodium gradient.
- SGLTs sodium-dependent glucose cotransporters
- SGLT2 is almost exclusively expressed in the kidney, whereas SGLT1 is expressed additionally in other tissues like intestine, colon, skeletal and cardiac muscle.
- SGLT3 has been found to be a glucose sensor in interstitial cells of the intestine without any transport function.
- a patient in the context of the present invention is an individual showing renal hyperfiltration or at risk of developing renal hyperfiltration.
- Such patient is an individual diagnosed or showing type 1 diabetes mellitus (see for example Melsom et al. Diabetes Care 2011; DOI: 10.2337/dc11-0235).
- Such patient is for example an individual diagnosed or showing type 1 diabetes mellitus, MODY, LADA, pre-diabetes, morbid obesity, congenital or acquired obstructive uro/nephropathy, progressive chronic kidney disease (CKD) and/or acute renal failure (ARF).
- Such patient is also for example a renal transplant recipient, a renal transplant donors, or an unilateral total or partial nephrectomized patient.
- a patient in the context of the present invention is an individual having glomerular filtration rate (GFR) equal to or above 125 ml/min/1.73 m 2 .
- GFR glomerular filtration rate
- a patient in the context of the present invention is an individual having a GFR equal to or above 140 ml/min/1.73 m 2 .
- the GFR of the individual is measured by a method known in the art or as described herein.
- the SGLT2 inhibitor is the glucopyranosyl-substituted benzene derivative of the formula (1.9) (I.9) 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-[4-( (S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene.
- the definition of the above listed glucopyranosyl-substituted benzene derivative of the formula (1.9) also comprises its hydrates, solvates and polymorphic forms thereof, and prodrugs thereof.
- an advantageous crystalline form is described in the international patent applciation WO 2006/117359 and WO 2011/039107 .
- the crystalline form possess good solubility properties which enable a good bioavailability of the SGLT2 inhibitor.
- the crystalline form is physico-chemically stable and thus provide a good shelf-life stability of the pharmaceutical composition.
- a preferred crystalline form (I.9X) of the compound (1.9) can be characterized by an X-ray powder diffraction pattern that comprises peaks at 18.84, 20.36 and 25.21 degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern (XRPD) is made using CuK ⁇ 1 radiation.
- XRPD X-ray powder diffraction pattern
- said X-ray powder diffraction pattern comprises peaks at 14.69, 18.84, 19.16, 19.50, 20.36 and 25.21 degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ 1 radiation.
- said X-ray powder diffraction pattern comprises peaks at 14.69, 17.95, 18.43, 18.84, 19.16, 19.50, 20.36, 22.71, 23.44, 24.81, 25.21 and 25.65 degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ 1 radiation.
- the crystalline form (I.9X) is characterised by an X-ray powder diffraction pattern, made using CuK ⁇ 1 radiation, which comprises peaks at degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ) as contained in Table 1.
- Table 1 X-ray powder diffraction pattern of the crystalline form (I.9X) (only peaks up to 30° in 2 ⁇ are listed): 2 ⁇ [°] d-value [ ⁇ ] Intensity I/I 0 [%] 4.46 19.80 8 9.83 8.99 4 11.68 7.57 4 13.35 6.63 14 14.69 6.03 42 15.73 5.63 16 16.20 5.47 8 17.95 4.94 30 18.31 4.84 22 18.43 4.81 23 18.84 4.71 100 19.16 4.63 42 19.50 4.55 31 20.36 4.36 74 20.55 4.32 13 21.18 4.19 11 21.46 4.14 13 22.09 4.02 19 22.22 4.00 4 22.71 3.91 28 23.44 3.79 27 23.72 3.75 3 24.09 3.69 3 24.33 3.66 7
- the crystalline form (I.9X) is characterised by an X-ray powder diffraction pattern, made using CuK ⁇ 1 radiation, which comprises peaks at degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ) as shown in Figure 1 .
- the crystalline form (I.9X) is characterised by a melting point of about 149°C ⁇ 3°C (determined via DSC; evaluated as onset-temperature; heating rate 10 K/min). The obtained DSC curve is shown in Figure 2 .
- ⁇ location-sensitive detector
- Cu-anode Cu-anode
- the above described 2 ⁇ values should be considered accurate to ⁇ 0.1 degrees 2 ⁇ , in particular ⁇ 0.05 degrees 2 ⁇ . That is to say, when assessing whether a given sample of crystals of the compound (1.9) is the crystalline form in accordance with the invention, a 2 ⁇ value which is experimentally observed for the sample should be considered identical with a characteristic value described above if it falls within ⁇ 0.1 degrees 2 ⁇ of the characteristic value, in particular if it falls within ⁇ 0.05 degrees 2 ⁇ of the characteristic value.
- the melting point is determined by DSC (Differential Scanning Calorimetry) using a DSC 821 (Mettler Toledo).
- a pharmaceutical composition or dosage form according to the present invention comprises the compound (1.9), wherein at least 50 % by weight of the compound (1.9) is in the form of its crystalline form (I.9X) as defined hereinbefore.
- at least 80 % by weight, more preferably at least 90 % by weight of the compound (1.9) is in the form of its crystalline form (I.9X) as defined hereinbefore.
- the dissolution properties of the pharmaceutical composition and dosage form is affected inter alia by the particle size and particle size distribution of the respective active pharmaceutical ingredient.
- the active pharmaceutical ingredients preferably have a particle size distribution such that at least 90 % of the respective active pharmaceutical ingredient particles, with regard to the distribution by volume, has a particle size smaller than 200 ⁇ m, i.e. X90 ⁇ 200 ⁇ m.
- the glucopyranosyl-substituted benzene derivative of the (1.9), preferably its crystalline form (I9.X), preferably has a particle size distribution (by volume) such that at least 90 % of the respective active pharmaceutical ingredient has a particle size smaller than 200 ⁇ m, i.e. X90 ⁇ 200 ⁇ m, preferably X90 ⁇ 150 ⁇ m. More preferably the particle size distribution is such that X90 ⁇ 100 ⁇ m, even more preferably X90 ⁇ 90 ⁇ m.
- the particle size distribution is preferably such that X90 ⁇ 1 ⁇ m, more preferably X90 ⁇ 5 ⁇ m, even more preferably X90 ⁇ 10 ⁇ m. Therefore preferred particle size distributions are such that 1 ⁇ m ⁇ X90 ⁇ 200 ⁇ m, particularly 1 ⁇ m ⁇ X90 ⁇ 150 ⁇ m, more preferably 5 ⁇ m ⁇ X90 ⁇ 150 ⁇ m, even more preferably 5 ⁇ m ⁇ X90 ⁇ 100 ⁇ m, even more preferably 10 ⁇ m ⁇ X90 ⁇ 100 ⁇ m.
- Another preferred example is 20 ⁇ m ⁇ X90 ⁇ 50 ⁇ m.
- the glucopyranosyl-substituted benzene derivative of the formula (1.9), preferably its crystalline form (I9.X), preferably has a particle size distribution (by volume) such that X50 ⁇ 90 ⁇ m, more preferably X50 ⁇ 75 ⁇ m, even more preferably X50 ⁇ 50 ⁇ m, most preferably X50 ⁇ 40 ⁇ m.
- the particle size distribution is preferably such that X50 ⁇ 1 ⁇ m, more preferably X50 ⁇ 5 ⁇ m, even more preferably X50 ⁇ 8 ⁇ m.
- preferred particle size distributions are such that 1 ⁇ m ⁇ X50 ⁇ 90 ⁇ m, particularly 1 ⁇ m ⁇ X50 ⁇ 75 ⁇ m, more preferably 5 ⁇ m ⁇ X50 ⁇ 75 ⁇ m, even more preferably 5 ⁇ m ⁇ X50 ⁇ 50 ⁇ m.
- a preferred example is 8 ⁇ m ⁇ X50 ⁇ 40 ⁇ m.
- the glucopyranosyl-substituted benzene derivative of the formula (1.9), preferably its crystalline form (I9.X), preferably has a particle size distribution (by volume) such that X10 ⁇ 0.1 ⁇ m, more preferably X10 ⁇ 0.5 ⁇ m, even more preferably X10 ⁇ 1 ⁇ m, in particular X10 ⁇ 2 ⁇ m.
- a pharmaceutical composition or pharmaceutical dosage form according to this invention may preferably be characterized by the above specified particle size distributions X90, X50 and/or X10 or one of the following embodiments:
- Embodiment Glucopyranosyl-substituted benzene derivative (1.9) 1 X90 ⁇ 200 ⁇ m 2 1 ⁇ m ⁇ X90 ⁇ 150 ⁇ m 3 5 ⁇ m ⁇ X90 ⁇ 150 ⁇ m 4 10 ⁇ m ⁇ X90 ⁇ 100 ⁇ m 5 X90 ⁇ 150 ⁇ m 1 ⁇ m ⁇ X50 ⁇ 75 ⁇ m 6 X90 ⁇ 150 ⁇ m 5 ⁇ m ⁇ X50 ⁇ 50 ⁇ m 7 X90 ⁇ 150 ⁇ m 1 ⁇ m ⁇ X50 ⁇ 75 ⁇ m X10 ⁇ 0.1 ⁇ m 8 X90 ⁇ 150 ⁇ m 5 ⁇ m ⁇ X50 ⁇ 50 ⁇ m 0.5 ⁇ m
- the value X90 refers to the 90% value of the volume distribution measured using a laser diffractometer. In other words, for the purposes of the present invention, the X90 value denotes the particle size below which 90% of the quantity of particles is found based on the volume distribution.
- the value X50 refers to the 50% value (median) of the volume distribution measured using a laser diffractometer. In other words, for the purposes of the present invention, the X50 value denotes the particle size below which 50% of the quantity of particles is found based on the volume distribution.
- the value X10 refers to the 10% value of the volume distribution measured using a laser diffractometer. In other words, for the purposes of the present invention, the X10 value denotes the particle size below which 10% of the quantity of particles is found based on the volume distribution.
- X90, X50, X10 values hereinbefore and hereinafter are by volume and determined by laser-diffraction method, in particular low angle laser light scattering, i.e. Fraunhofer diffraction.
- the laser diffraction method is sensitive to the volume of a particle and provides a volume-average particle size, which is equivalent to the weight-average particle size if the density is constant.
- the skilled artesian knows that the results of the particle size distribution determination by one technique can be correlated with that from another technique, for example on an empirical basis by routine experimentation.
- the particle size distribution in the pharmaceutical composition or dosage form can be determined by microscopy, in particular electron microscopy or scanning electron microscopy.
- a pharmaceutical composition according to the invention typically comprises one or more diluents, one or more disintegrants and optionally one or more binders. Some of the excipients may have two or more functions at the same time, e.g. act as a filler and a binder.
- Suitable diluents according to the invention are for example, lactose, in particular lactose monohydrate, cellulose and derivatives, such as powdered cellulose, microcrystalline or silicified microcrystalline cellulose, cellulose acetate, starches and derivatives such as pregelatinized starch, corn starch, wheat starch, rice starch, potato starch, sterilizable maize, sodium chloride, calcium carbonate, calcium phosphate, particularly dibasic calcium phosphate, calcium sulphate, dicalcium or tricalcium phosphate, magnesium carbonate, magnesium oxide, sugars and derivatives such as confectioner's sugar, fructose, sucrose, dextrates, dextrin, D-sorbitol sulfobutylether ⁇ -cyclodextrin, dextrose, polydextrose, trehalose, maltose, maltitol, mannitol, maltodextrin, sorbitol, inulin, xylitol,
- Suitable disintegrants according to the invention are for example powdered cellulose, crospovidone, croscarmellose sodium, docusate sodium, low-substituted hydroxypropyl cellulose, magnesium aluminum silicate, microcrystalline cellulose, polacrilin potassium, sodium starch glycolate, starch, particularly pregelatinized starch and corn starch.
- a preferred disintegrant is croscarmellose sodium.
- Binders are for example naturally occurring or partially or totally synthetic polymers selected from acacia, agar, alginic acid, carbomers, carmellose sodium, carrageenan, cellulose acetate phthalate, ceratonia, chitosan, confectionar's sugar, copovidone, povidone, cottonseed oil, dextrate, dextrin, dextrose, polydextrose, maltodextrin, maltose, cellulose and derivatives thereof such as microcrystalline cellulose, methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl celluloses, carboxymethylcelluloses, hypromelloses (cellulose hydroxypropyl methyl ether), starch and derivatives thereof, such as pregelatinized starch, hydroxypropylstarch, corn starch, gelatin, glyceryl behenate, traga
- the pharmaceutical composition according to the present invention may also comprise one or more lubricants.
- Suitable lubricants according to the invention are stearic acid as well as salts thereof including talc, sodium stearate, calcium stearate, zinc stearate, magnesium stearate, sodium stearyl fumarate, glyceryl monostearate, particularly magnesium stearate, polyethylene glycols, in particular polyethylene glycol with a molecular weight in a range from about 4400 to about 9000, hydrogenated castor oil, fatty acid, for example fumaric acid, and salts of fatty acids, in particular the calcium, magnesium, sodium or pottasium salts thereof, for example calcium behenate, calcium stearate, sodium stearyl fumarate or magnesium stearate (for example (e.g. HyQual®, Mallinckrodt), glycerides such as glyceryl behenate (Compritol® 888), Dynasan® 118 or Boeson®
- the pharmaceutical composition according to the present invention may also comprise one or more glidants.
- Suitable glidants according to the invention are silicon dioxide, particularly colloidal silicon dioxide (e.g. Aerosil®, Cab-O-Sil®), stearic acid as well as salts thereof including sodium stearate, calcium stearate, zinc stearate, magnesium stearate, magnesium silicate, calcium silicate, magnesium trisilicate and talc.
- Preferred glidants are colloidal silicon dioxide and talc.
- a pharmaceutical composition according to the instant invention comprises Amount (% by weight) Active ingredient 0.5 - 25 One or more diluents 65 - 93 One or more binders 1 - 5 One or more disintegrants 1 - 4
- additional additives ad 100 %
- the active ingredient is the compound of the formula (1.9) or its crystalline form (I.9X).
- a pharmaceutical composition according to the instant invention comprises Amount (% by weight) Active ingredient 0.5 - 25 One or more diluents 65 - 90 One or more binders 1 - 5 One or more disintegrants 1 - 3
- additional additives ad 100 %
- the active ingredient is the compound of the formula (1.9) or its crystalline form (I.9X).
- a pharmaceutical composition according to the instant invention comprises Amount (% by weight) Active ingredient 0.5 - 25 Lactose monohydrate 28 - 70 Microcrystalline cellulose 20 - 50 Hydroxypropyl cellulose 1 - 5 Croscarmellose sodium 1 - 4
- additional additives ad 100 %
- the active ingredient is a compound of the formula (1.9) or its crystalline form (I.9X).
- a pharmaceutical composition according to the instant invention comprises Amount (% by weight) Active ingredient 0.5 - 25 Lactose monohydrate 35 - 90 Microcrystalline cellulose 0 - 30 Hydroxypropyl cellulose 1 - 5 Croscarmellose sodium 1 - 3 Additional additives ad 100 %
- the active ingredient is a compound of the formula (1.9) or its crystalline form (I.9X).
- the ratio of said disintegrant to said binder in a pharmaceutical composition of the present invention is between 1.5:3.5 and 1:1.
- the active ingredient represents 25% or less of the weight of the pharmaceutical composition.
- the active ingredient represents 0.5% to 25% of the weight of the pharmaceutical composition. More preferably, the active ingredient represents 1.0% to 20% of the weight of the pharmaceutical composition. Even more preferably, the active ingredient represents 2.0% to 15% of the weight of the pharmaceutical composition.
- ranges of the amount of the glucopyranosyl-substituted benzene derivative to be employed in the pharmaceutical dosage form according to this invention are described. These ranges refer to the amounts to be administered per day with respect to an adult patient, in particular to a human being, for example of approximately 70 kg body weight, and can be adapted accordingly with regard to an administration 1, 2, 3, 4 or more times daily and with regard to other routes of administration and with regard to the age of the patient. The ranges of the dosage and amounts are calculated for the active ingredient.
- a preferred amount of the glucopyranosyl-substituted benzene derivative (1.9) or its crystalline form (I.9X) is in a range from 0.5 to 100 mg, preferably from 0.5 to 50 mg, even more preferably from 1 to 25 mg, even more preferably 5 to 25 mg, particularly 10 to 25 mg.
- Preferred dosages of the glucopyranosyl-substituted benzene derivative are for example 1 mg, 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg and 50 mg, in particular 10 mg and 25 mg.
- a pharmaceutical composition according to the present invention may be comprised in a tablet, a capsule or a film-coated tablet,
- a tablet comprising a pharmaceutical composition according to the present invention comprises a lubricant, such as magnesium stearate.
- a lubricant such as magnesium stearate.
- Such lubricant may be present in a concentration of 0.25 - 2 % in said tablet.
- a tablet comprising a pharmaceutical composition according to the present invention comprises a glidant, such as colloidal silicon dioxide.
- a glidant such as colloidal silicon dioxide.
- Such glidant may be present in a concentration of 0.25 - 2 % in said tablet.
- a tablet according to the invention may be film-coated.
- a film coat represents 2-5% by weight of the total composition and comprises preferably a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
- An exemplary coat composition may comprise hydroxypropylmethyl-cellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and optionally iron oxide, including iron oxide red and/or yellow.
- the pharmaceutical dosage form according to the invention has dissolution properties such that after 45 minutes at least 75 %, preferably at least 90 % by weight of the pharmaceutical active ingredient is dissolved. In another embodiment after 30 minutes at least 75 %, preferably at least 90 % by weight of the pharmaceutical active ingredien is dissolved. In another embodiment after 15 minutes at least 75 %, preferably at least 90 % by weight of the pharmaceutical active ingredient is dissolved.
- the dissolution properties can be determined in a standard dissolution test, for example as described in pharmacopoeias, such as the USP31-NF26 S2, chapter 711 (dissolution).
- the pharmaceutical dosage form according to the invention has disintegration properties such that within 40 minutes, alternatively within 30 minutes, preferably within 20 minutes, more preferably within 15 minutes the pharmaceutical dosage form is disintegrated.
- the disintegration properties can be determined in a standard disintegration test, for example as described in pharmacopoeias, such as the USP31-NF26 S2, chapter 701 (disintegration).
- the pharmaceutical dosage form according to the invention has a high content uniformity, preferably within a range from 85 to 115 %, more preferably from 90 to 110 %, even more preferably from 95 to 105 % by weight with regard to the pharmaceutical ingredient.
- the content uniformity can be determined in a standard test using for example randomly 10 selected pharmaceutical dosage forms, for example as described in pharmacopoeias.
- a dosage form according to this invention such as a tablet, capsule or film-coated tablet, may be prepared by methods well-known to the one skilled in the art.
- Suitable methods of manufacturing a tablet include compression of the pharmaceutical composition in the form of a powder, i.e. direct compression, or compression of the pharmaceutical composition in the form of granules, and if needed with additional excipients.
- Granules of the pharmaceutical composition according to the invention may be prepared by methods well-known to the one skilled in the art. Preferred methods for the granulation of the active ingredients together with the excipients include wet granulation, for example high shear wet granulation and fluidized bed wet granulation, dry granulation, also called roller compaction.
- the granulation liquid are the solvent alone or a preparation of one or more binders in a solvent or mixture of solvents.
- Suitable binders are described hereinbefore. Examples are hypromellose, hydroxypropyl cellulose, povidone and copovidone.
- Suitable solvents are for example purified water, ethanol, methanol, isopropanol, acetone, preferably purified water, including mixtures thereof.
- the solvent is a volatile component, which does not remain in the final product.
- the one or more active ingredients and the other excipients, in particular the one or more diluents and the one or more disintegrants, usually with exception of the lubricant, are premixed and granulated with the granulation liquid, for example using a high shear granulator.
- the wet granulation step is usually followed by one or more drying and sieving steps. For example a drying oven or a fluid bed dryer can then be used for drying.
- the dried granules are sieved through an appropriate sieve.
- the mixture is blended in a suitable blender, for example a free fall blender, followed by addition of the one or more lubricants, for example magnesium stearate, and final blending in the blender.
- An exemplary wet granulation process for making a pharmaceutical composition according to the instant invention comprises the steps of:
- the present invention also provides a pharmaceutical composition obtainable by the above process.
- An exemplary direct compression process according to the present invention for making a pharmaceutical composition comprises the steps of:
- the present invention also provides a pharmaceutical composition obtainable by the above process.
- An exemplary dry granulation process according to the present invention for making a pharmaceutical composition comprises the steps of:
- the size of the granules according to the present invention is in the range from 25 to 800 ⁇ m, for example from 40 ⁇ m to 500 ⁇ m.
- the size of the granules may be measured via sieve analysis, for example with a sonic sifter. In one embodiment, at least 80 %, at least 90 %, or at least 95 % by weight of the granules is in the given range.
- this invention refers to patients requiring treatment or prevention, it relates primarily to treatment and prevention in humans, but the pharmaceutical composition may also be used accordingly in veterinary medicine in mammals.
- adult patients are preferably humans of the age of 18 years or older.
- patients are adolescent humans, i.e. humans of age 6 to 17 years, for example 10 to 17 years, preferably of age 13 to 17 years.
- a treatment or prophylaxis according to this invention is advantageously suitable in those patients in need of such treatment or prophylaxis who are diagnosed of one or more of the conditions selected from the group consisting of overweight and obesity, in particular class I obesity, class II obesity, class III obesity, morbid obesity, visceral obesity and abdominal obesity.
- a treatment or prophylaxis according to this invention is advantageously suitable in those patients in which a weight increase should preferably be avoided.
- the pharmaceutical composition according to the present invention allow a reduction of the HbA1c value to a desired target range, for example ⁇ 7 % and preferably ⁇ 6.5 %, for a higher number of patients and for a longer time of therapeutic treatment compared with a corresponding monotherapy or a therapy using only two of the combination partners.
- the pharmaceutical composition according to this invention and in particular the SGLT2 inhibitor therein exhibits a very good efficacy with regard to glycemic control, in particular in view of a reduction of fasting plasma glucose, postprandial plasma glucose and/or glycosylated hemoglobin (HbA1c).
- HbA1c fasting plasma glucose, postprandial plasma glucose and/or glycosylated hemoglobin
- composition according to this invention is advantageously applicable in those patients who show one, two or more of the following conditions:
- the amount of the SGLT2 inhibitor to be employed in the pharmaceutical composition for use in methods according to this invention are described. These ranges refer to the amounts to be administered per day with respect to an adult patient, in particular to a human being, for example of approximately 70 kg body weight, and can be adapted accordingly with regard to an administration 1, 2, 3, 4 or more times daily and with regard to other routes of administration and with regard to the age of the patient.
- the pharmaceutical composition is preferably administered orally. Other forms of administration are possible and described hereinafter.
- the one or more dosage forms comprising the SGLT2 inhibitor is oral or usually well known.
- the amount of the SGLT2 inhibitor in the pharmaceutical composition for use in methods according to this invention is preferably the amount usually recommended for a monotherapy using said SGLT2 inhibitor.
- the preferred dosage range of the SGLT2 inhibitor is in the range from 0.5 mg to 200 mg, even more preferably from 1 to 100 mg, most preferably from 1 to 50 mg per day.
- the oral administration is preferred. Therefore, a pharmaceutical composition may comprise the hereinbefore mentioned amounts, in particular from 1 to 50 mg or 1 to 25 mg.
- Particular dosage strengths e.g. per tablet or capsule
- the application of the active ingredient may occur up to three times a day, preferably one or two times a day, most preferably once a day.
- compositions for use in methods are employed by administering the pharmaceutical composition comprising the SGLT2 inhibitor (1.9) to the patient.
- An oral administration is preferred.
- the SGLT2 inhibitor in particular the compound (1.9) is the only active pharmaceutical ingredient administered to the patient.
- the pharmaceutical compositions for use in methods relate to a mono-therapy.
- the SGLT2 inhibitor (1.9) is administered to the patient in combination with one or more other active pharmaceutical ingredients.
- the methods relate to a combination therapy.
- the other active pharmaceutical ingredient is a medicament for the treatment of diabetes mellitus, in particular type 1 diabetes mellitus or type 2 diabetes mellitus. Therefore the pharmaceutical compositions for use in methods according to the present invention also relate to a combination therapy with one or more other antidiabetics.
- the other active pharmaceutical ingredient as a medicament for the treatment of diabetes mellitus is preferably selected from the group consisting of metformin, a DPPIV inhibitor, an insulin, a PPARgamma agonist, a GLP-1 receptor agonist, a glinide, a sulfonylurea or an alpha-glucosidase blocker, including combinations thereof.
- Specific examples of other pharmaceutical ingredients are metformin, linagliptin, repaglinide, liraglutide, pioglitazone and glimepirid. Combinations of a SGLT2 inhibitor and an antidiabetic active pharmaceutical ingredient are described for example in WO 2008/055940 .
- compositions for use in methods according to the present invention may be of particular advantage in those patients who are pretreated with an antidiabetic medicament and who have a risk to develop hyperfiltration or who are diagnosed of having hyperfiltration.
- the co-administration of the SGLT2 inhibitor (1.9) in combination with the other antidiabetc may allow to treat hyperfiltration, including to lower the risk of developing hyperfiltration, while lowering the blood-glucose levels through excretion of glucose via the urine and thus having the opportunity to lower the dosage of the other antidiabetic medicament.
- SGLT2 inhibitor a weight loss and/or a reduction of body fat may be achieved or an increase of weight and/or body fat which would be provoked by the other antidiabetic may be prevented or attenuated.
- the blood pressure may be lowered which is of particular advantage in patients having an elevated risk of high blood pressure or being diagnosed of having a high blood pressure.
- the SGLT2 inhibitor (1.9) and the other active pharmaceutical ingredient, in particular an antidiabetic, may be formulated into one pharmaceutical composition for combined administration or may be formulated into separate pharmaceutical compositions for combined or separate administration.
- metformin includes its salts, such as metformin hydrochloride.
- metformin may be comprised in a pharmaceutical composition for immediate release, for modified release, sustained release or for extended release.
- Metformin may be administered orally using pharmaceutical compositions, dosages and administration schemes as known in the prior art.
- a preferred dosage range for metformin is 500 to 2000 mg once or twice daily, for example 500 mg, 850 mg or 1000 mg, preferably once or twice daily.
- the SGLT2 inhibitor (1.9) and metformin may be administered in combination, for example simultaneously, and when they are administered in alternation, for example successively in separate formulations.
- compositions comprising a SGLT2 inhibitor, in particular the compound (1.9), and metformin are described in WO 2011/039337 .
- Preferred dosages of the combination compound (I.9)/ metformin are for example 5 mg/ 500 mg, 12.5 mg/ 500 mg, 5 mg/ 850 mg, 12.5 mg/ 850 mg, 5 mg/ 1000 mg and 12.5 mg/ 1000 mg.
- the DPPIV inhibitor may be selected from the group consisting of linagliptin, sitagliptin, saxagliptin, vildagliptin, alogliptin, denagliptin, melogliptin, carmegliptin, dutogliptin, tenegliptin, gosogliptin, anagliptin, gemigliptin and bisegliptin.
- the DPPIV inhibitor may be administered orally using pharmaceutical compositions, dosages and administration schemes as known in the prior art.
- a preferred DPPIV inhibitor is linagliptin. As linagliptin is primarily excreted by bile and the gut a higher safety in patients with renal conditions or dysfunction is seen.
- a combination of the compound (1.9) with linagliptin is of particular interest in the pharmaceutical compositions according to this invention.
- a preferred dosage range for linagliptin is 0.5 to 20 mg once or twice daily, for example 0.5 mg, 1 mg, 2.5 mg, 5 mg or 10 mg, preferably once daily.
- the SGLT2 inhibitor, in particular the compound (1.9), and the DPPIV inhibitor, for example linagliptin may be administered in combination, for example simultaneously, and when they are administered in alternation, for example successively in separate formulations. Methods for the combined administration of a SGLT2 inhibitor and a DPPIV inhibitor are described for example in WO 2009/022007 .
- compositions comprising a SGLT2 inhibitor, in particular the compound (1.9), and the DPPIV inhibitor, for example linagliptin, are described in WO 2010/092124 .
- Preferred dosages of the combination compound (I.9)/ linagliptin are for example 10 mg/ 5 mg, 12.5 mg/ 5 mg and 25 mg/ 5 mg.
- compositions for use in methods according to the present invention relate to an administration of the SGLT2 inhibitor (1.9) and the DPPIV inhibitor, for example linagliptin, in combination or alternation with another active pharmaceutical ingredient for the treatment of diabetes mellitus.
- Another active pharmaceutical ingredient is metformin.
- Combinations of an SGLT2 inhibitor, a DPPIV inhibitor and a third active pharmaceutical ingredient are described in the WO 2010/092125 .
- the PPARgamma agonist is preferably a thiazolidindione, in particular pioglitazone or rosiglitazone.
- the term "pioglitazone” as employed herein refers to pioglitazone, including its enantiomers, mixtures thereof and its racemate, or a pharmaceutically acceptable salt thereof such as the hydrochloride salt.
- the term "rosiglitazone” as employed herein refers to rosiglitazone, including its enantiomers, mixtures thereof and its racemate, or a pharmaceutically acceptable salt thereof such as the maleate salt.
- insulin in the scope of the present invention relates to insulin and insulin analogs being used in the therapy of patients, in particular humans, which includes normal insulin, human insulin, insulin derivatives, zinc insulins and insulin analogues, including formulations thereof with modified release profiles. in particular as used in the therapy of humans.
- insulin in the scope of the present invention covers the following types of insulins:
- GLP-1 receptor agonist in the scope of the present invention includes, without being limited, exogenous GLP-1 (natural or synthetic), GLP-1 analogues and other substances (whether peptidic or non-peptidic, e.g. small molecules) which promote signalling through the GLP-1 receptor.
- the exogenous GLP-1 includes natural and synthetic GLP-1, in particular human GLP-1.
- the GLP-1 analogues include longer acting analogues also which are resistant to or have reduced susceptibility to enzymatic degradation, for example by DPP-4 and/or NEP 24.11.
- GLP-1 analogues are selected from the group consisting of exenatide (exendin-4); exenatide LAR (long acting release formulation of exenatide); liraglutide; taspoglutide; semaglutide; albiglutide; lixisenatide; dulaglutide; and the PEGylated GLP-1 compound comprising the amino acid sequence according to the claim 1 of WO 2006/124529 (the disclosure of which is incorporated herein) and the GLP-1 derivative comprising the amino acid sequence according to SEQ ID NO:21 as disclosed in the WO 2009/020802 (the disclosure of which is incorporated herein).
- Combinations of an insulin and a GLP-1 receptor agonist, in particular a GLP-1 analog, may be used in combination with the SGLT-2 inhibitor (1.9) in the pharmaceutical compositions for use in methods according to this invention also.
- Examples of glinides are repaglinide and nateglinide.
- Examples of sulfonylureas are glibenclamide, tolbutamide, glimepiride, glipizide, glyburide, gliclazide.
- Examples of alpha-glucosidase blockers are miglitol, acarbose and voglibose.
- a manufacture comprises (a) a pharmaceutical composition comprising the SGLT2 inhibitor according to the present invention and (b) a label or package insert which comprises instructions that the medicament is to be administered.
- the desired dose of the pharmaceutical composition according to this invention may conveniently be presented in a once daily or as divided dose administered at appropriate intervals, for example as two, three or more doses per day.
- the pharmaceutical composition may be formulated for oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration in liquid or solid form or in a form suitable for administration by inhalation or insufflation. Oral administration is preferred.
- the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active ingredient with one or more pharmaceutically acceptable carriers, like liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
- the pharmaceutical composition may be formulated in the form of tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, oral solutions, syrups, dry syrups, chewable tablets, troches, effervescent tablets, drops, suspension, fast dissolving tablets, oral fast-dispersing tablets, etc..
- the pharmaceutical composition and the dosage forms preferably comprises one or more pharmaceutical acceptable carriers which must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- pharmaceutically acceptable carriers are known to the one skilled in the art.
- compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, including soft gelatin capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion, for example as syrups, elixirs or self-emulsifying delivery systems (SEDDS).
- the active ingredients may also be presented as a bolus, electuary or paste.
- Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
- the tablets may be coated according to methods well known in the art.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.
- compositions according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
- the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
- compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
- suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound(s) with the softened or melted carrier(s) followed by chilling and shaping in moulds.
- compositions for use in methods according to this invention show advantageous effects in the treatment and prevention of those diseases and conditions as described hereinbefore.
- Advantageous effects may be seen for example with respect to efficacy, dosage strength, dosage frequency, pharmacodynamic properties, pharmacokinetic properties, fewer adverse effects, convenience, compliance, etc..
- compositions and methods within the scope of the invention may be tested by animal models known in the art.
- compositions for use in methods according to this invention can be tested in genetically hyperinsulinemic or diabetic animals like db/db mice, ob/ob mice, Zucker Fatty (fa/fa) rats or Zucker Diabetic Fatty (ZDF) rats.
- they can be tested in animals with experimentally induced diabetes like HanWistar or Sprague Dawley rats pretreated with streptozotocin.
- the following examples show the beneficial effect on glycemic control and hyperfiltration of the pharmaceutical compositions according to the present invention.
- the SGLT-2 inhibitor is 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-[4-( (S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, preferably in the crystalline form (I.9X).
- GFR glomerular filtration rate
- Additional parameters of renal function may also be measured. These include:
- active substance denotes the SGLT-2 inhibitor of the formula (1.9) or its crystalline form (I.9X).
- the active pharmaceutical ingredient or active sustance i.e. the compound (1.9), preferably in the crystalline form (I.9X), is milled with a suitable mill like pin- or jet-mill in order to obtain the desired particle size distribution before manufacturing of the pharmaceutical composition or dosage form.
- Active substance Batch 1 Active substance Batch 2 X10 1,8 ⁇ m 1,7 ⁇ m X50 18,9 ⁇ m 12,1 ⁇ m X90 45,3 ⁇ m 25,9 ⁇ m
- Example 1 Dry ampoule containing 50 mg of active substance per 10 ml
- Active substance and mannitol are dissolved in water. After packaging the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.
- Example 2 Dry ampoule containing 25 mg of active substance per 2 ml
- Active substance and mannitol are dissolved in water. After packaging, the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.
- Example 3 Tablet containing 50 mg of active substance
- composition (1) Active substance 50.0 mg (2) Mannitol 98.0 mg (3) Maize starch 50.0 mg (4) Polyvinylpyrrolidone 15.0 mg (5) Magnesium stearate 2.0 mg 215.0 mg
- Diameter of the tablets 9 mm.
- Example 4 Capsules containing 50 mg of active substance
- (1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing. This powder mixture is packed into size 3 hard gelatin capsules in a capsule filling machine.
- Example 5 Tablets containing 2.5mg, 5mg, 10mg, 25mg, 50mg of active substance
- Example 7 Pharmaceutical composition containing other fillers
- Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
- a glucopyranosyl-substituted benzene derivative according to the present invention, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix.
- the pre-mix is moistened with the granulation liquid and subsequently granulated.
- the moist granulate is sieved through a suitable sieve.
- the granulate is dried at about 60 °C inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4 % is obtained.
- the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- Magnesium stearate is passed through a sieve for delumping and added to the granulate. Subsequently the final blend is produced by final blending in a suitable blender for three minutes and compressed into tablet cores.
- Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
- the tablet cores are coated with the coating suspension to a weight gain of about 3 % to produce film-coated tablets.
- Example 8 Pharmaceutical composition containg other disintegrant
- Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
- An glucopyranosyl-substituted benzene derivative according to the present invention, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix.
- the pre-mix is moistened with the granulation liquid and subsequently granulated.
- the moist granulate is sieved through a suitable sieve.
- the granulate is dried at about 60 °C inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4 % is obtained.
- the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- Crospovidone is added to the dried granulate and mixed for 5 minutes to produce the main blend.
- Magnesium stearate is passed through a sieve for delumping and added to main blend.
- the final blend is produced by final blending in a suitable blender for three minutes and compressed into 8 mm round tablet cores with a compression force of 16 kN.
- Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
- the tablet cores are coated with the coating suspension to a weight gain of about 3 % to produce film-coated tablets.
- the following formulation variants can be obtained: Ingredient mg/ tablet mg/ tablet mg/ tablet mg/ tablet mg/ tablet Active substance 2.5 5.0 10.0 25.0 50.0 Mannitol 127.5 125.0 120.0 105.0 210.0 Microcrystalline Cellulose 39.0 39.0 39.0 39.0 78.0 Crospovidone 2.0 2.0 2.0 2.0 4.0 Copovidone 5.4 5.4 5.4 10.8 Magnesium stearate 3.6 3.6 3.6 7.2 Film coat 5.0 5.0 5.0 5.0 10.0 Total 185.0 185.0 185.0 185.0 185.0 370.0
- the tablet hardness, the friability, the content uniformity, the disintegration time and the dissolution properties are determined as described hereinbefore.
- Example 10 Tablets containing 0.5mg, 5mg, 25mg, 100mg of active substance
- Active substance 0.5 mg mg/per tablet 5 mg mg/per tablet 25 mg mg/per tablet 100 mg mg/per tablet
- Wet granulation active substance 2.5000 5.000 25.00 100.00 Lactose Monohydrate 60.00 55.00 42.00 168.00 Microcrystalline Cellulose 20.00 20.00 38.00 152.00 Hyd roxypropyl Cellulose 5.00 5.00 7.50 30.00 Croscarmellose Sodium 4.00 4.00 6.00 24.00 Purified Water q.s. q.s. q.s. Dry Adds Microcrystalline Cellulose 10.00 10.00 30.00 120.00 Colloidal silicon dioxide - 0.50 0.75 3.00 Magnesium stearate 0.50 0.50 0.75 3.00 Total 100.00 100.00 150.00 600.00
- the active substance e.g. the compound (1.9), preferably in the crystalline form (I.9X), hydroxypropyl cellulose, and croscarmellose sodium are mixed in a blender. This premix is mixed with lactose monohydrate and a portion of microcrystalline cellulose. The resulting blend is granulated with purified water. Multiple granulation subparts may be produced for an individual tablet batch, as needed, depending on the batch size and equipment used.
- the granulation is discharged onto dryer trays and dried.
- the granulation is then milled.
- the remainder of the microcrystalline cellulose is added (as a premix with the colloidal silicon dioxide for all strengths other than the 0.5 mg) to the milled granulation, and mixed.
- the magnesium stearate is premixed with a portion of the blend, screened into the remainder of the granulation, and mixed.
- the final tablet blend is compressed into tablets using a tablet press.
- the finished tablets are packaged using a suitable container closure system.
- Example 11 Tablets containing 1mg, 5mg, 25mg of active substance
- the active substance i.e. the compound (1.9), preferably in the crystalline form (I.9X) is passed through a screen and added to a blender or a high shear granulator.
- the hydroxypropyl cellulose and croscarmellose sodium are passed through a screen, added to the drug substance, and mixed.
- the intra-granular portion of microcrystalline cellulose is passed through a screen into a high shear granulator and mixed with the drug substance premix. Lactose is then added by passing the material through a screen into the granulator and mixing.
- the resulting blend is granulated with purified water. For larger batches, multiple granulation subparts may be produced for an individual tablet batch, as needed, depending on the batch size and equipment used.
- the granulation is discharged onto dryer trays and dried.
- the granulation is then passed through a mill into a blender.
- the colloidal silicon dioxide is pre-mixed with a portion of the extra-granular microcrystalline cellulose.
- This premix is passed through a mill into the blender, followed by the remaining extra-granular microcrystalline cellulose, and mixed with the milled granulation.
- the magnesium stearate is premixed with a portion of the blend, passed through a mill into the remainder of the granulation, and mixed.
- the final tablet blend is compressed into tablets using a tablet press.
- the finished tablets are packaged using a suitable container closure system.
- Disintegration test was performed as described in USP31-NF26 S2, chapter 701 (disintegration).
- the standard dissolution test is described in USP31-NF26 S2, chapter 711 (dissolution).
- the paddle method (Apparatus 2) with an agitation speed of 50 rpm was used.
- the dissolution media is 900 mL 0.05 M Potassium phosphate buffer pH 6.8 at a temperature of 37°C. Samples are taken after 10, 15, 20, 30 and 45 minutes. The samples are analyzed via HPLC.
- Particle size distribution measurement is performed for example via light scattering or laser diffraction technique.
- the powder is fed into a laser diffraction spectrometer for example by means of a dispersing unit.
- the test method is described below in detail: Equipment: Laser Diffraction Spectrometer Sympatec HELOS Particle Sizer.
- the instrument is set up according to the manufacturer's recommendation and using the manufacturer provided software.
- the sample container is thoroughly mixed and tumbled prior to removing a portion of the sample to ensure that a representative sample is tested.
- Duplicate samples are prepared by using a spatula to transfer approximately 100 mg of a sample into the ASPIROS glass vials and cap the vials. The capped cials are placed into the feeder.
- compositions comprising the compound (1.9) (API 1) and linagliptin (API 2) and their manufacture are provided.
- the active pharmaceutical ingredients API 1 and API 2 are processed in one granulation step and a one-layer tablet is pressed.
- copovidone is dissolved in purified water at ambient temperature (about 20°C) to produce a granulation liquid.
- API 1, API 2, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix.
- the pre-mix is moistened with the granulation liquid and subsequently granulated.
- the moist granulate is sieved through a suitable sieve.
- the granulate is dried at about 60 °C inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4 % is obtained.
- the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- Crospovidone and talc are added to the dried granulate and mixed for 5 minutes to produce the main blend.
- Magnesium stearate is passed through a sieve for delumping and added to main blend.
- the final blend is produced by final blending in a suitable blender for three minutes and compressed into 8 mm round tablet cores with a compression force of 16 kN.
- Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide, mannitol and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
- the tablet cores are coated with the coating suspension to a weight gain of about 3 % to produce film-coated tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21157166.6A EP3854404A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
SI201231915T SI2729151T1 (sl) | 2011-07-08 | 2012-07-03 | Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe |
PL12730993T PL2729151T3 (pl) | 2011-07-08 | 2012-07-03 | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
RS20210582A RS61827B1 (sr) | 2011-07-08 | 2012-07-03 | Farmaceutska kompozicija, postupci za lečenje i njihova primena |
HRP20210978TT HRP20210978T1 (hr) | 2011-07-08 | 2021-06-19 | Farmaceutski pripravak, postupci za liječenje i njegove uporabe |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161505598P | 2011-07-08 | 2011-07-08 | |
PCT/EP2012/062922 WO2013007557A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21157166.6A Division-Into EP3854404A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
EP21157166.6A Division EP3854404A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2729151A1 EP2729151A1 (en) | 2014-05-14 |
EP2729151B1 true EP2729151B1 (en) | 2021-03-31 |
Family
ID=46420221
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21157166.6A Pending EP3854404A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
EP12730993.8A Revoked EP2729151B1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21157166.6A Pending EP3854404A1 (en) | 2011-07-08 | 2012-07-03 | Pharmaceutical composition, methods for treating and uses thereof |
Country Status (22)
Country | Link |
---|---|
US (5) | US20130035298A1 (da) |
EP (2) | EP3854404A1 (da) |
JP (2) | JP2014520778A (da) |
KR (1) | KR20140041697A (da) |
CN (2) | CN103732230A (da) |
AR (1) | AR087729A1 (da) |
AU (1) | AU2012283229B2 (da) |
BR (1) | BR112014000380A2 (da) |
CA (1) | CA2837787C (da) |
CY (1) | CY1124307T1 (da) |
DK (1) | DK2729151T3 (da) |
EA (1) | EA025497B1 (da) |
ES (1) | ES2871904T3 (da) |
HR (1) | HRP20210978T1 (da) |
HU (1) | HUE054621T2 (da) |
LT (1) | LT2729151T (da) |
MX (1) | MX2014000010A (da) |
PL (1) | PL2729151T3 (da) |
PT (1) | PT2729151T (da) |
RS (1) | RS61827B1 (da) |
SI (1) | SI2729151T1 (da) |
WO (1) | WO2013007557A1 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
CN102307577A (zh) | 2009-02-13 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
WO2011039108A2 (en) | 2009-09-30 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AU2014255727B2 (en) | 2013-04-18 | 2019-07-25 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
EP3485890B1 (en) * | 2014-01-23 | 2023-05-10 | Boehringer Ingelheim Vetmedica GmbH | Sglt2 inhibitors for treatment of metabolic disorders in canine animals |
JP6571100B2 (ja) | 2014-03-04 | 2019-09-04 | 大塚製薬株式会社 | イオヘキソール粉末及びそれを使用する方法 |
US20170319539A1 (en) * | 2014-10-01 | 2017-11-09 | Mylan Laboratories Ltd. | Amorphous Empagliflozin |
JP2018509400A (ja) * | 2015-03-27 | 2018-04-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | セムブラギリンを含む医薬製剤 |
KR20230028568A (ko) * | 2016-03-16 | 2023-02-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 엠파글리플로진을 포함하는 약제학적 조성물 및 이의 용도 |
CA3039745A1 (en) * | 2016-11-10 | 2018-05-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2020089761A1 (en) * | 2018-11-01 | 2020-05-07 | Glenmark Pharmaceuticals Limited | Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof |
US11655240B1 (en) * | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092877A1 (de) | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2008055940A2 (en) | 2006-11-09 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
WO2010092124A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof |
WO2010092123A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
WO2006064033A2 (en) | 2004-12-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
PL1881850T3 (pl) | 2005-05-13 | 2011-03-31 | Lilly Co Eli | Pegylowane związki GLP-1 |
DE602006017566D1 (de) | 2005-08-30 | 2010-11-25 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
TW200745075A (en) | 2005-09-08 | 2007-12-16 | Boehringer Ingelheim Int | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
AR059489A1 (es) | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
JP2010507629A (ja) | 2006-10-27 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用 |
US7879806B2 (en) | 2006-11-06 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture |
WO2009020802A2 (en) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
CN102307577A (zh) | 2009-02-13 | 2012-01-04 | 贝林格尔.英格海姆国际有限公司 | 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途 |
JP5736377B2 (ja) | 2009-09-30 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)ベンジル]ベンゼンの結晶形の調製方法 |
WO2011039108A2 (en) | 2009-09-30 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
-
2012
- 2012-07-02 US US13/539,713 patent/US20130035298A1/en not_active Abandoned
- 2012-07-03 EP EP21157166.6A patent/EP3854404A1/en active Pending
- 2012-07-03 PT PT127309938T patent/PT2729151T/pt unknown
- 2012-07-03 CN CN201280038791.6A patent/CN103732230A/zh active Pending
- 2012-07-03 PL PL12730993T patent/PL2729151T3/pl unknown
- 2012-07-03 RS RS20210582A patent/RS61827B1/sr unknown
- 2012-07-03 SI SI201231915T patent/SI2729151T1/sl unknown
- 2012-07-03 AU AU2012283229A patent/AU2012283229B2/en active Active
- 2012-07-03 LT LTEP12730993.8T patent/LT2729151T/lt unknown
- 2012-07-03 KR KR1020147000445A patent/KR20140041697A/ko not_active Application Discontinuation
- 2012-07-03 ES ES12730993T patent/ES2871904T3/es active Active
- 2012-07-03 JP JP2014517770A patent/JP2014520778A/ja active Pending
- 2012-07-03 EP EP12730993.8A patent/EP2729151B1/en not_active Revoked
- 2012-07-03 HU HUE12730993A patent/HUE054621T2/hu unknown
- 2012-07-03 BR BR112014000380A patent/BR112014000380A2/pt not_active IP Right Cessation
- 2012-07-03 MX MX2014000010A patent/MX2014000010A/es active IP Right Grant
- 2012-07-03 EA EA201400119A patent/EA025497B1/ru not_active IP Right Cessation
- 2012-07-03 CA CA2837787A patent/CA2837787C/en active Active
- 2012-07-03 CN CN201611176372.5A patent/CN106692126A/zh active Pending
- 2012-07-03 DK DK12730993.8T patent/DK2729151T3/da active
- 2012-07-03 WO PCT/EP2012/062922 patent/WO2013007557A1/en active Application Filing
- 2012-07-06 AR ARP120102475A patent/AR087729A1/es unknown
-
2016
- 2016-01-07 JP JP2016001599A patent/JP2016121156A/ja active Pending
-
2018
- 2018-03-27 US US15/936,927 patent/US20180214468A1/en not_active Abandoned
-
2019
- 2019-11-26 US US16/695,324 patent/US20200268777A1/en not_active Abandoned
-
2021
- 2021-06-14 US US17/346,475 patent/US20220096505A1/en not_active Abandoned
- 2021-06-14 CY CY20211100523T patent/CY1124307T1/el unknown
- 2021-06-19 HR HRP20210978TT patent/HRP20210978T1/hr unknown
-
2023
- 2023-09-06 US US18/461,850 patent/US20230405032A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092877A1 (de) | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2008055940A2 (en) | 2006-11-09 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
WO2010092124A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof |
WO2010092123A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia |
Non-Patent Citations (19)
Title |
---|
"Klinische Pathophysiologie", 1982, article SIEGENTHALER: "Niere und albeitende harnwege", pages: 986 - 988, XP055876956 |
ABDUL-GHANI MUHAMMAD A., ET AL: "Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes", ENDOCRINE REVIEWS, THE ENDOCRINE SOCIETY, US, vol. 32, no. 4, 1 August 2011 (2011-08-01), US , pages 515 - 531, XP055879244, ISSN: 0163-769X, DOI: 10.1210/er.2010-0029 |
ANONYMOUS: "Inulin-Clearance", WIKIPEDIA, 29 June 2021 (2021-06-29), pages 1 - 2, XP055876978 |
CHERNEY DAVID Z I ET AL: "Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus", CIRCULATION, vol. 129, no. 5, February 2014 (2014-02-01), pages 587 - 597, ISSN: 0009-7322(print) * |
CHERNEY ET AL.: "Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus", CIRCULATION, vol. 129, 4 February 2014 (2014-02-04), pages 587 - 597, XP055876983 |
CHERNEY, ET AL.: "Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus", CIRCULATION, vol. 129, 4 February 2014 (2014-02-04), pages 587 - 597, XP055876983 |
G. PEREZ LÓPEZ ET AL.: "Sodium-glucose cotransporter 2 inhibitors (SGLT2): from renal glycosuria to the treatment of type 2 diabetes mellitus", NEFROLOGIA, vol. 30, no. 6, 2010, pages 618 - 25, XP055857728, DOI: 10.3265/Nefrologia.pre2010.Sep.10494 |
G. VERVOORT ET AL.: "Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 35, 2005, pages 330 - 336, XP071216262, DOI: 10.1111/j.1365-2362.2005.01497.x |
GALLE J.: "Glomeruläre Filtrationsrate: Fallstricke der Berechnung", DTSCH ARTZEBL, vol. 113, no. 4, 2016, pages 33 - 34, XP055876980 |
JERUMS ET AL.: "The clinical significance of hyperfiltration in diabetes", DIABETOLOGIA, vol. 53, 2010, pages 2093 - 2104, XP019836222 |
MALATIALI SLAVA; FRANCIS ISSAM; BARAC-NIETO MARIO: "Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats.", EXPERIMENTAL DIABETES RESEARCH, vol. 2008, 1 January 2008 (2008-01-01), pages 305403 - 305403-7, XP009161745, DOI: 10.1155/2008/305403 |
PERSSON ET AL.: "Tubular reabsorption and diabetes-induced glomerular hyperfiltration", ACTA PHYSIOL, 2010, pages 3 - 10, XP009161708, DOI: 10.1111/j.1748-1716.2010.02147.x |
R GREMPLER ET AL: "Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Introduction", DIABETES OBESITY AND METABOLISM JUNE, vol. 14, 1 January 2012 (2012-01-01), pages 83 - 90, XP055228524, DOI: 10.1111/j.1463-1326.2011.01517.x * |
VALLON ET AL.: "Sodium-glucose transport: role in diabetes mellitus and potential clinical implications", CURR OPIN NEPHROL HYPERTENS, vol. 19, no. 5, 2010, pages 425 - 431, XP055876974 |
VALLON VOLKER ET AL: "Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD., US, vol. 10, no. 12, 1 December 1999 (1999-12-01), US , pages 2569 - 2576, XP009161748, ISSN: 1046-6673 |
VALLON VOLKER, ET AL: "Glomerular Hyperfiltration and the Salt Paradox in Early Type 1 Diabetes Mellitus: A Tubulo-Centric View", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD., US, vol. 14, no. 2, 1 February 2003 (2003-02-01), US , pages 530 - 537, XP055879242, ISSN: 1046-6673, DOI: 10.1097/01.ASN.0000051700.07403.27 |
VALLON VOLKER; RICHTER KERSTIN; BLANTZ ROLAND C; THOMSON SCOTT; OSSWALD HARTMUT: "Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption", J AM SOC NEPHROL, vol. 10, 1999, pages 2569 - 2576, XP009161748 |
WISEMAN MARTIN J, ET AL: "Effect of Blood Glucose Control on Increased Glomerular Filtration Rate and Kidney Size in Insulin-Dependent Diabetes", N ENGL J MED ., vol. 312, no. 10, 7 March 1985 (1985-03-07), pages 617 - 621, XP055879241 |
Y. CHUN-HSU ET AL.: "Discovery of Novel N-beta-D-xylosylindole Derivatives as Sodium- Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes", J MED CHEM, vol. 54, 2011, pages 166 - 178, XP009161759, DOI: 10.1021/jm101072y |
Also Published As
Publication number | Publication date |
---|---|
DK2729151T3 (da) | 2021-06-28 |
BR112014000380A2 (pt) | 2017-02-14 |
PT2729151T (pt) | 2021-05-25 |
AR087729A1 (es) | 2014-04-16 |
CN103732230A (zh) | 2014-04-16 |
NZ618546A (en) | 2016-02-26 |
CN106692126A (zh) | 2017-05-24 |
WO2013007557A1 (en) | 2013-01-17 |
CA2837787C (en) | 2021-09-14 |
JP2016121156A (ja) | 2016-07-07 |
LT2729151T (lt) | 2021-05-25 |
SI2729151T1 (sl) | 2021-06-30 |
JP2014520778A (ja) | 2014-08-25 |
US20230405032A1 (en) | 2023-12-21 |
US20220096505A1 (en) | 2022-03-31 |
ES2871904T3 (es) | 2021-11-02 |
HRP20210978T1 (hr) | 2021-09-17 |
HUE054621T2 (hu) | 2021-09-28 |
MX2014000010A (es) | 2014-02-27 |
US20130035298A1 (en) | 2013-02-07 |
AU2012283229A1 (en) | 2014-01-09 |
RS61827B1 (sr) | 2021-06-30 |
EP2729151A1 (en) | 2014-05-14 |
KR20140041697A (ko) | 2014-04-04 |
EP3854404A1 (en) | 2021-07-28 |
EA201400119A1 (ru) | 2014-08-29 |
CY1124307T1 (el) | 2022-07-22 |
EA025497B1 (ru) | 2016-12-30 |
CA2837787A1 (en) | 2013-01-17 |
US20200268777A1 (en) | 2020-08-27 |
AU2012283229B2 (en) | 2017-06-15 |
PL2729151T3 (pl) | 2021-10-18 |
US20180214468A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230405032A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
US20220313716A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
US20230285432A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
US20180289678A1 (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
EP2187879B1 (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
US20110098240A1 (en) | Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor | |
AU2014200258B2 (en) | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia | |
AU2018202278B2 (en) | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia | |
NZ618546B2 (en) | Pharmaceutical composition, methods for treating and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140210 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20150630 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20191024 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200424 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20201020 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1376168 Country of ref document: AT Kind code of ref document: T Effective date: 20210415 Ref country code: DE Ref legal event code: R096 Ref document number: 602012074982 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2729151 Country of ref document: PT Date of ref document: 20210525 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210518 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20210978 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210623 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20210331 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E020807 Country of ref document: EE Effective date: 20210528 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20210401538 Country of ref document: GR Effective date: 20210709 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: RO Payment date: 20210628 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 37444 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20210978 Country of ref document: HR Payment date: 20210628 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20210978 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E054621 Country of ref document: HU |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20210721 Year of fee payment: 10 Ref country code: RS Payment date: 20210629 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210331 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20210723 Year of fee payment: 10 Ref country code: LU Payment date: 20210726 Year of fee payment: 10 Ref country code: CZ Payment date: 20210702 Year of fee payment: 10 Ref country code: EE Payment date: 20210723 Year of fee payment: 10 Ref country code: BG Payment date: 20210721 Year of fee payment: 10 Ref country code: FI Payment date: 20210722 Year of fee payment: 10 Ref country code: AT Payment date: 20210722 Year of fee payment: 10 Ref country code: IT Payment date: 20210727 Year of fee payment: 10 Ref country code: HR Payment date: 20210703 Year of fee payment: 10 Ref country code: IE Payment date: 20210726 Year of fee payment: 10 Ref country code: FR Payment date: 20210729 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2871904 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211102 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20210721 Year of fee payment: 10 Ref country code: BE Payment date: 20210721 Year of fee payment: 10 Ref country code: SI Payment date: 20210624 Year of fee payment: 10 Ref country code: SK Payment date: 20210701 Year of fee payment: 10 Ref country code: TR Payment date: 20210701 Year of fee payment: 10 Ref country code: SE Payment date: 20210721 Year of fee payment: 10 Ref country code: LV Payment date: 20210716 Year of fee payment: 10 Ref country code: NO Payment date: 20210723 Year of fee payment: 10 Ref country code: GR Payment date: 20210726 Year of fee payment: 10 Ref country code: HU Payment date: 20210802 Year of fee payment: 10 Ref country code: IS Payment date: 20210712 Year of fee payment: 10 Ref country code: DE Payment date: 20210721 Year of fee payment: 10 Ref country code: ES Payment date: 20210928 Year of fee payment: 10 Ref country code: DK Payment date: 20210723 Year of fee payment: 10 Ref country code: GB Payment date: 20210722 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1376168 Country of ref document: AT Kind code of ref document: T Effective date: 20210331 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602012074982 Country of ref document: DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20210702 Year of fee payment: 10 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MDE Opponent name: GENERICS (UK) LIMITED Ref country code: FI Ref legal event code: MDE Opponent name: SANDOZ AG |
|
26 | Opposition filed |
Opponent name: GENERICS (UK) LIMITED Effective date: 20211228 Opponent name: SANDOZ AG Effective date: 20211223 |
|
RDAF | Communication despatched that patent is revoked |
Free format text: ORIGINAL CODE: EPIDOSNREV1 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R103 Ref document number: 602012074982 Country of ref document: DE Ref country code: DE Ref legal event code: R064 Ref document number: 602012074982 Country of ref document: DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LT Payment date: 20220623 Year of fee payment: 11 |
|
RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM9A Effective date: 20320703 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MGE |
|
27W | Patent revoked |
Effective date: 20220528 |
|
GBPR | Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state |
Effective date: 20220528 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: NF Ref document number: 20210401538 Country of ref document: GR Effective date: 20221010 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: PNEV Ref document number: P20210978 Country of ref document: HR |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20220622 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: MF4A Ref document number: E020807 Country of ref document: EE Effective date: 20221004 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20220701 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MA03 Ref document number: 1376168 Country of ref document: AT Kind code of ref document: T Effective date: 20220528 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 37444 Country of ref document: SK Effective date: 20220703 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20220708 Year of fee payment: 11 Ref country code: MK Payment date: 20220624 Year of fee payment: 11 Ref country code: AL Payment date: 20220712 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20230314 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MC4A Ref document number: E 37444 Country of ref document: SK Effective date: 20220528 |